TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer - PubMed (original) (raw)
. 2018 Apr;37(16):2165-2180.
doi: 10.1038/s41388-017-0095-x. Epub 2018 Jan 30.
Affiliations
- PMID: 29379164
- DOI: 10.1038/s41388-017-0095-x
TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer
Ken-Ichi Takayama et al. Oncogene. 2018 Apr.
Abstract
Prostate cancer growth is promoted by the gene regulatory action of androgen receptor (AR) and its downstream signals. The aberrant dysfunction of tumor suppressor p53 has an important role in the prognosis of cancer. We previously found that androgen treatments translocate p53 to the cytoplasm. The mechanism of this translocation depends on sumoylation of p53 by complex of SUMO E3 ligase RanBP2 with androgen-induced GTPase-activating protein-binding protein 2 (G3BP2). Here, we identified tripartite motif-containing protein 25 (TRIM25)/estrogen-responsive finger protein (Efp) as a novel interacting partner of G3BP2 protein complex. Then, we demonstrated that TRIM25 knockdown resulted in p53 downstream activation for cell cycle inhibition and apoptosis induction in LNCaP and 22Rv1 cells. In contrast, overexpression of TRIM25 promoted prostate cancer cell proliferation and inhibited apoptosis by docetaxel treatment in LNCaP cells. We observed that p53 activity was reduced by mechanism of G3BP2-mediated nuclear export in TRIM25-overexpressing prostate cancer cells. We also found TRIM25 is important for G3BP2/RanBP2-mediated p53 modification. Clinically, we newly demonstrated that TRIM25 is a prognostic factor for prostate cancer patients. Expression of TRIM25 is significantly associated with cytoplasmic p53 expression and G3BP2. Moreover, TRIM25 knockdown results in reduced tumor growth and increased p53 activity in the mouse xenograft model of prostate cancer. Thus, our findings show that overexpression of TRIM25 promoted prostate cancer cell proliferation and cell survival by modulating p53 nuclear export mechanism with G3BP2 interaction.
Similar articles
- Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.
Ashikari D, Takayama K, Tanaka T, Suzuki Y, Obinata D, Fujimura T, Urano T, Takahashi S, Inoue S. Ashikari D, et al. Oncogene. 2017 Nov 9;36(45):6272-6281. doi: 10.1038/onc.2017.225. Epub 2017 Jul 10. Oncogene. 2017. PMID: 28692047 - Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer.
Takayama KI, Suzuki T, Fujimura T, Takahashi S, Inoue S. Takayama KI, et al. Mol Cancer Res. 2018 May;16(5):846-856. doi: 10.1158/1541-7786.MCR-17-0471. Epub 2018 Jan 29. Mol Cancer Res. 2018. PMID: 29378906 - The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
Wang S, Kollipara RK, Humphries CG, Ma SH, Hutchinson R, Li R, Siddiqui J, Tomlins SA, Raj GV, Kittler R. Wang S, et al. Oncotarget. 2016 Oct 4;7(40):64921-64931. doi: 10.18632/oncotarget.11915. Oncotarget. 2016. PMID: 27626314 Free PMC article. - Efp/TRIM25 and Its Related Protein, TRIM47, in Hormone-Dependent Cancers.
Azuma K, Inoue S. Azuma K, et al. Cells. 2022 Aug 8;11(15):2464. doi: 10.3390/cells11152464. Cells. 2022. PMID: 35954308 Free PMC article. Review. - The role of Trim25 in development, disease and RNA metabolism.
Heikel G, Choudhury NR, Michlewski G. Heikel G, et al. Biochem Soc Trans. 2016 Aug 15;44(4):1045-50. doi: 10.1042/BST20160077. Biochem Soc Trans. 2016. PMID: 27528750 Review.
Cited by
- Stress granule-related genes during embryogenesis of an invertebrate chordate.
Drago L, Pennati A, Rothbächer U, Ashita R, Hashimoto S, Saito R, Fujiwara S, Ballarin L. Drago L, et al. Front Cell Dev Biol. 2024 Aug 1;12:1414759. doi: 10.3389/fcell.2024.1414759. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39149517 Free PMC article. - Tripartite-motif 3 represses ovarian cancer progression by downregulating lactate dehydrogenase A and inhibiting AKT signaling.
Cong Y, Cui X, Shi Y, Pan X, Huang K, Geng Z, Xu P, Ge L, Zhu J, Xu J, Jia X. Cong Y, et al. Mol Cell Biochem. 2024 Feb 17. doi: 10.1007/s11010-023-04920-y. Online ahead of print. Mol Cell Biochem. 2024. PMID: 38367118 - TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO.
Chen Y, Xu X, Ding K, Tang T, Cai F, Zhang H, Chen Z, Qi Y, Fu Z, Zhu G, Dou Z, Xu J, Chen G, Wu Q, Ji J, Zhang J. Chen Y, et al. J Exp Clin Cancer Res. 2024 Feb 2;43(1):39. doi: 10.1186/s13046-024-02964-6. J Exp Clin Cancer Res. 2024. PMID: 38303029 Free PMC article. - Degradation of AZGP1 suppresses apoptosis and facilitates cholangiocarcinoma tumorigenesis via TRIM25.
Yun H, Jeong HR, Kim DY, You JE, Lee JU, Kang DH, Koh DI, Ryu YS, Bae S, Jin DH. Yun H, et al. J Cell Mol Med. 2024 Feb;28(3):e18104. doi: 10.1111/jcmm.18104. Epub 2024 Jan 6. J Cell Mol Med. 2024. PMID: 38183356 Free PMC article. - Therapeutic, diagnostic and prognostic values of TRIM proteins in prostate cancer.
Li X, Bai Y, Feng K, Chu Z, Li H, Lin Z, Tian L. Li X, et al. Pharmacol Rep. 2023 Dec;75(6):1445-1453. doi: 10.1007/s43440-023-00534-9. Epub 2023 Nov 3. Pharmacol Rep. 2023. PMID: 37921966 Review.
References
- Cell. 2009 Jul 23;138(2):245-56 - PubMed
- Biochem Biophys Res Commun. 2004 Jul 2;319(3):795-800 - PubMed
- Proc Natl Acad Sci U S A. 2000 May 23;97(11):6049-54 - PubMed
- Nat Med. 2004 Jan;10(1):33-9 - PubMed
- DNA Cell Biol. 2005 Apr;24(4):264-9 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous